|
KMID : 1151620210060020155
|
|
Journal of Retina
2021 Volume.6 No. 2 p.155 ~ p.161
|
|
|
Development of Subretinal Hemorrhage during Treatment of Neovascular Age-related Macular Degeneration Using a Treat-and-extend Regimen: A Case Report
|
|
Kim Jae-Hui
|
|
|
Abstract
|
|
|
Purpose: To report a case of subretinal hemorrhage that developed during treatment of neovascular age-related macular degeneration (nAMD) using a treat-and-extend (TAE) regimen.
Case summary: A 69-year-old woman was diagnosed with nAMD. Three monthly ranibizumab injections were performed as an initial treatment. Then, treatment was performed as-needed for 32 months. At 32 months, the treatment regimen was switched to TAE, which is characterized by continuous injections with 1 to 3 months interval regardless of recurrence. During the 31-month TAE period, 14 anti-vascular endothelial growth factor injections were performed. At 31 months, the injection interval was 2 months, and no subretinal or intraretinal fluid was observed on optical coherence tomography. Best-corrected visual acuity (BCVA) was 0.2. At 33 months, subretinal hemorrhage developed with deterioration of BCVA to 0.04. Three ranibizumab injections were performed, but subretinal hemorrhage did not resolve.
Conclusions: Extensive subretinal hemorrhage can develop even in patients treated with TAE regimen. Further studies are required to more effectively prevent the hemorrhage.
|
|
|
KEYWORD
|
|
|
Age related macular degeneration, Choroidal neovascularization, Retinal hemorrhage
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|